Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults | Zendy

UrmilaM Thatte | Zendy; Kannan Sridharan | Zendy; Rachna Kataria | Zendy; Drishti Tolani | Zendy; Shital R. Bendkhale | Zendy; NithyaJ Gogtay | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults

Author(s) -

UrmilaM Thatte,

Kannan Sridharan,

Rachna Kataria,

Drishti Tolani,

Shital R. Bendkhale,

NithyaJ Gogtay

Publication year - 2016

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.186191

Subject(s) - cyp2c19 , clopidogrel , p2y12 , pharmacodynamics , genotype , bioavailability , medicine , platelet , pharmacology , polymorphism (computer science) , population , pharmacokinetics , aspirin , biology , genetics , gene , environmental health

CYP2C19 and P2Y12 polymorphisms have been claimed to alter the pharmacodynamic response to clopidogrel. ABCB1 polymorphism has been associated with the efflux of clopidogrel resulting in decreased bioavailability. Due to paucity of data from Indian population, the present study was undertaken to evaluate the association of genetic polymorphisms of CYP2C19, P2Y12, and ABCB1 with inhibition of platelet aggregation (IPA) by clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research